Aurora Cannabis and Radient Technologies Announce First Commercial Delivery of Cannabis Derivatives

 Aurora Cannabis Inc. and Radient Technologies Inc. announced today that Aurora has taken delivery of Radient’s first commercial batch of finished cannabis derivatives, from Radient’s proprietary extraction platform. With this first batch, Radient has proven its enhanced ability to produce cannabinoid derivatives at commercial scale, and will continue to scale up production at Radient’s cannabis facility in Edmonton, reaching an expected eventual annual throughput of approximately 300,000 kg of cannabis biomass at this single location. 

The partnership between Radient and Aurora was established in 2017 after the completion of a Research Joint Venture that validated Radient’s MAPTM extraction technology was capable of superior cannabinoid extraction at commercial scale. For Aurora, the relationship with Radient forms an important component of its derivative product strategy, providing a greater return on the biomass allocated for extraction, favourable cost advantages, and significantly increased extraction capacity. 

High Volume Throughput Technology

In Radient’s deliveries to Aurora, commercial scale batches of dried cannabis biomass were fully processed and refined within a 24-hour period, due mainly to the speed of initial extraction and the unique, continuous flow nature of Radient’s platform.

Radient’s technology platform is designed for high extraction efficiencies and high-volume throughput of cannabinoids available in the plant biomass. This is anticipated to provide Aurora with cost and volume advantages in delivering a broad suite of derivative products.

Radient’s Hemp facility in Edmonton will have an annual throughput of approximately 3,200,000 kg of hemp biomass. Phase one is expected to be completed in calendar Q3 of 2019.  

Management Commentary

“Aurora recognized early that high-throughput, high-quality extraction technologies would be a competitive advantage in a rapidly developing cannabis industry,” said Terry Booth, CEO of Aurora. “Our investment will begin to pay dividends with Radient achieving fully licensed, commercial status. Once scaled up, the addition of Radient’s technology will significantly increase our ability to deliver high-value cannabis products at scale, complementing our existing internal extraction capabilities, which will support a full suite of derivative products.”  

Mr. Booth continued, “Cannabidiol (CBD) derived from hemp requires the level of throughput that Radient’s technology and state-of-the-art second facility will provide to existing and future medical, wellness and consumer markets. We look forward to working with Denis and the Radient team to further our global position in the derivative markets.” 

Denis Taschuk, CEO of Radient, added, “Achieving commercial production and sales is a crucial milestone we are very proud to have achieved. We have worked diligently over the past two years towards this inflection point, together with our partner Aurora and we are now very well positioned for accelerated growth going forward. We appreciate the patience our shareholders have shown as we executed on our transformational business plan. Aurora’s execution in the global medical cannabis space inspired us with their continued confidence in our technology.”